CRISPR/CAS9-Mediated genome editing of miRNA-155 inhibits proinflammatory cytokine production by RAW264.7 Cells

69Citations
Citations of this article
99Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

MicroRNA 155 (miR-155) is a key proinflammatory regulator in clinical and experimental rheumatoid arthritis (RA). Here we generated a miR-155 genome knockout (GKO) RAW264.7 macrophage cell line using the clustered regulatory interspaced short palindromic repeat (CRISPR)/CRISPR-associated protein 9 (CAS9) technology. While upregulating the Src homology-2 domain-containing inositol 5-phosphatase 1 (SHIP1), the miR-155 GKO line is severely impaired in producing proinflammatory cytokines but slightly increased in osteoclastogenesis upon treatment with receptor activator of nuclear factor- B ligand (RANKL). Taken together, our results suggest that genome editing of miR-155 holds the potential as a therapeutic strategy in RA.

Cite

CITATION STYLE

APA

Jing, W., Zhang, X., Sun, W., Hou, X., Yao, Z., & Zhu, Y. (2015). CRISPR/CAS9-Mediated genome editing of miRNA-155 inhibits proinflammatory cytokine production by RAW264.7 Cells. BioMed Research International, 2015. https://doi.org/10.1155/2015/326042

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free